Your browser doesn't support javascript.
loading
The MNK1/2-eIF4E Axis Supports Immune Suppression and Metastasis in Postpartum Breast Cancer.
Guo, Qianyu; Bartish, Margarita; Gonçalves, Christophe; Huang, Fan; Smith-Voudouris, Julian; Krisna, Sai Sakktee; Preston, Samuel E J; Emond, Audrey; Li, Vivian Z; Duerr, Claudia U; Gui, Yirui; Cleret-Buhot, Aurélie; Thebault, Pamela; Lefrère, Hanne; Lenaerts, Liesbeth; Plourde, Dany; Su, Jie; Mindt, Barbara C; Hewgill, Shannon A; Cotechini, Tiziana; Hindmarch, Charles C T; Yang, William; Khoury, Elie; Zhan, Yao; Narykina, Valeria; Wei, Yuhong; Floris, Giuseppe; Basik, Mark; Amant, Frédéric; Quail, Daniela F; Lapointe, Réjean; Fritz, Jörg H; Del Rincon, Sonia V; Miller, Wilson H.
Afiliação
  • Guo Q; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Bartish M; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Gonçalves C; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Huang F; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Smith-Voudouris J; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Krisna SS; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Preston SEJ; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Emond A; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Li VZ; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Duerr CU; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Gui Y; Department of Physiology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Cleret-Buhot A; McGill University Research Centre on Complex Traits, Montréal, Québec, Canada.
  • Thebault P; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Lefrère H; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Lenaerts L; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Plourde D; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Su J; Department of Microbiology & Immunology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Mindt BC; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Hewgill SA; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
  • Cotechini T; Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montréal, Québec, Canada.
  • Hindmarch CCT; Institut du cancer de Montréal, Montreal, Canada.
  • Yang W; Département de Médecine, Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada.
  • Khoury E; Clinical Immuno-Monitoring Core Facility, CRCHUM, Montréal, Québec, Canada.
  • Zhan Y; Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Narykina V; Department of Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Wei Y; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Floris G; Segal Cancer Centre, Lady Davis Institute and Jewish General Hospital, Montréal, Québec, Canada.
  • Basik M; McGill University Research Centre on Complex Traits, Montréal, Québec, Canada.
  • Amant F; Department of Microbiology & Immunology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Quail DF; McGill University Research Centre on Complex Traits, Montréal, Québec, Canada.
  • Lapointe R; Department of Microbiology & Immunology, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
  • Fritz JH; Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
  • Del Rincon SV; Queen's Cardiopulmonary Unit, Queen's University, Kingston, Ontario, Canada.
  • Miller WH; Department of Experimental Medicine, Faculty of Medicine, McGill University, Montréal, Québec, Canada.
Cancer Res ; 81(14): 3876-3889, 2021 07 15.
Article em En | MEDLINE | ID: mdl-33975880
ABSTRACT
Breast cancer diagnosed within 10 years following childbirth is defined as postpartum breast cancer (PPBC) and is highly metastatic. Interactions between immune cells and other stromal cells within the involuting mammary gland are fundamental in facilitating an aggressive tumor phenotype. The MNK1/2-eIF4E axis promotes translation of prometastatic mRNAs in tumor cells, but its role in modulating the function of nontumor cells in the PPBC microenvironment has not been explored. Here, we used a combination of in vivo PPBC models and in vitro assays to study the effects of inactivation of the MNK1/2-eIF4E axis on the protumor function of select cells of the tumor microenvironment. PPBC mice deficient for phospho-eIF4E (eIF4ES209A) were protected against lung metastasis and exhibited differences in the tumor and lung immune microenvironment compared with wild-type mice. Moreover, the expression of fibroblast-derived IL33, an alarmin known to induce invasion, was repressed upon MNK1/2-eIF4E axis inhibition. Imaging mass cytometry on PPBC and non-PPBC patient samples indicated that human PPBC contains phospho-eIF4E high-expressing tumor cells and CD8+ T cells displaying markers of an activated dysfunctional phenotype. Finally, inhibition of MNK1/2 combined with anti-PD-1 therapy blocked lung metastasis of PPBC. These findings implicate the involvement of the MNK1/2-eIF4E axis during PPBC metastasis and suggest a promising immunomodulatory route to enhance the efficacy of immunotherapy by blocking phospho-eIF4E.

SIGNIFICANCE:

This study investigates the MNK1/2-eIF4E signaling axis in tumor and stromal cells in metastatic breast cancer and reveals that MNK1/2 inhibition suppresses metastasis and sensitizes tumors to anti-PD-1 immunotherapy.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia de Imunossupressão / Fator de Iniciação 4E em Eucariotos Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Terapia de Imunossupressão / Fator de Iniciação 4E em Eucariotos Idioma: En Ano de publicação: 2021 Tipo de documento: Article